We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

News · June 10, 2021

EULAR 2021: Rituximab and JAK Inhibitor Use Associated With Worse Severity of COVID-19 in Rheumatoid Arthritis

Elevated odds for poor COVID-19 outcomes with rituximab highlights the urgent need for risk-mitigation strategies

PracticeUpdate Editorial Team

 

Further Reading